GLP1R and metabolic dysfunction-associated steatotic liver disease: Recently, NAFLD patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrated a favorable effect on liver fat content [20,21,22], indicating that these agents could be a novel therapeutic for NAFLD management.